Skip to main content
Aelis Farma logo

Aelis Farma — Investor Relations & Filings

Ticker · AELIS ISIN · FR0014007ZB4 LEI · 8945008D5R6WV7EXRN47 PA Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2022-03-18 Transaction in Own Shar…
Country FR France
Listing PA AELIS

About Aelis Farma

https://www.aelisfarma.com

Aelis Farma is a clinical-stage biopharmaceutical company that discovers and develops treatments for brain and central nervous system (CNS) disorders. The company has created a new class of drugs called Signaling Specific inhibitors of the CB1 receptor (CB1-SSi). This proprietary mechanism is designed to selectively inhibit the pathological signaling of the CB1 receptor, which is implicated in various brain diseases, while preserving its normal physiological functions and avoiding adverse effects associated with previous CB1-targeting drugs. The company's lead drug candidate, AEF0117, is in development for the treatment of Cannabis Use Disorder (CUD). Its second candidate, AEF0217, is being investigated for the treatment of cognitive deficits, including those associated with Down syndrome.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Transaction in Own Shares Classification · 99% confidence The document is a press release dated March 18, 2022, announcing two main items: 1) The implementation of a liquidity contract (contrat de liquidité) with ODDO BHF SCA, which is a mechanism to ensure stock market liquidity. 2) A description of the share repurchase program (programme de rachat d'actions) authorized by the board and shareholders. Share repurchase programs and related liquidity agreements are directly related to changes in the company's capital structure and share management. While it touches upon liquidity, the core subject is the authorization and mechanism for buying back its own shares. This aligns best with the 'Transaction in Own Shares' (POS) category, which covers share repurchase/issuance. It is not a general financing update (CAP) as it focuses specifically on repurchases, nor is it a general regulatory filing (RNS) because it fits the specific POS definition.
2022-03-18 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 98% confidence The document is a press release from Aelis Farma dated March 17, 2022, announcing the end of the stabilization period and the partial exercise of the over-allotment option related to a recent offering (IPO/listing on Euronext Paris). It details stabilization transactions and the resulting final capital structure. This type of announcement, which reports on the conclusion of a financing/offering event and subsequent market stabilization activities, fits best under 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains specifically to capital market activities.
2022-03-17 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 95% confidence The document is a press release dated March 10, 2022, detailing 'Opérations de stabilisation' (Stabilization Operations) conducted by Bryan Garnier Securities following the initial admission to trading of Aelis Farma's shares on Euronext Paris. It explicitly references EU regulations concerning market abuse (Règlement Abus de Marché) and stabilization measures (Règlement Délégué (UE) 2016/1052), providing a table of stabilization transactions (purchases). This type of announcement, related to post-IPO market support activities and regulatory disclosure requirements concerning share transactions, fits best under the category of Capital/Financing Update (CAP) or potentially a general Regulatory Filing (RNS). Since it specifically details financing/capital market activities (stabilization following an offering), CAP is a strong candidate. However, stabilization reports are often treated as specific regulatory disclosures related to capital market events. Given the options, 'CAP' covers financing activities, and stabilization is directly related to the offering/capital structure support. It is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K). It is a specific disclosure about market operations related to the issuance of shares, making 'CAP' (Capital/Financing Update) the most appropriate fit among the provided specific codes, although 'RNS' is a possibility if 'CAP' is reserved strictly for fundraising announcements. Since stabilization is a direct consequence of the capital raise/offering, CAP is selected.
2022-03-10 French
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 95% confidence The document is a press release dated March 3, 2022, detailing stabilization operations conducted by Bryan Garnier Securities following the initial admission to trading of Aelis Farma's shares on Euronext Paris. It explicitly references EU regulations concerning market abuse (MAR) and stabilization measures (Delegated Regulation (EU) 2016/1052). The core content is the disclosure of transactions (purchases) made by the stabilizing agent during the offering period. This type of announcement, which discloses specific details about market stabilization activities related to a recent offering or listing, is a specific type of regulatory disclosure. While it relates to capital raising/listing, the specific action being reported is the stabilization activity itself. This fits best under 'Capital/Financing Update' (CAP) as it is directly tied to the mechanics of the offering, or potentially 'Regulatory Filings' (RNS) as a general disclosure. However, given the specific nature of reporting stabilization activities post-IPO/listing, it is a direct consequence of a financing event. Since there is no specific code for 'Stabilization Report', and it is a formal disclosure related to the offering mechanics, 'CAP' (Capital/Financing Update) is the most appropriate fit among the provided options, as it details the post-listing market support mechanism. It is not an ER, IR, or 10-K, nor is it a simple announcement of a report (RPA).
2022-03-03 French
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 95% confidence The document is a press release dated February 24, 2022, detailing 'Opérations de stabilisation' (Stabilization Operations) conducted by Bryan Garnier Securities following the initial admission to trading of Aelis Farma shares on Euronext Paris. It explicitly references EU regulations (MAR, Delegated Regulation 2016/1052) concerning stabilization measures and provides a table detailing the purchase transactions, dates, prices, and volumes executed by the stabilizing agent. This activity is directly related to the initial offering/listing process and the subsequent management of the share price stabilization period. This type of announcement, which details the execution of stabilization activities post-IPO/listing, is a specific type of corporate action related to capital markets activity. While it relates to the offering, it is not the prospectus itself, nor is it a general capital change (SHA). It is a specific announcement regarding the post-listing market support mechanism. Given the options, this fits best under Capital/Financing Update (CAP) as it details actions taken immediately following a capital market event (the listing) to support the share price, or potentially Regulatory Filings (RNS) if no better fit exists. However, since it is a specific announcement about the mechanics of the offering/listing support, 'CAP' is the most appropriate fit among the choices, as stabilization is a financing/capital market activity. It is not an ER, IR, or 10-K. It is a specific regulatory disclosure related to the offering mechanics.
2022-02-24 French
Déclaration de participation
Major Shareholding Notification Classification · 99% confidence The document is titled "Déclaration de participation" (Declaration of Participation) and details the shareholding percentage (14.91%) held indirectly by Caisse des dépôts et consignations (CDC) via Bpifrance Investissement following the IPO of AELIS FARMA. This type of filing, reporting changes in significant share ownership or insider transactions, aligns best with the definition of Major Shareholding Notification (MRQ) or Director's Dealing (DIRS). Since this is a notification about a major shareholder crossing a threshold (14.91%) post-IPO, it fits the 'Major Shareholding Notification' category (MRQ). It is not an earnings release, annual report, or management discussion, but a specific regulatory disclosure regarding ownership structure.
2022-02-18 French

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.